These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11261327)

  • 1. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
    Ferrari T; Weber B; Pils S; Harbott J; Borkhardt A
    Ann Hematol; 2001 Feb; 80(2):72-3. PubMed ID: 11261327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
    Schoch C; Kohlmann A; Dugas M; Kern W; Hiddemann W; Schnittger S; Haferlach T
    Leukemia; 2005 Jul; 19(7):1224-8. PubMed ID: 15902281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes.
    Lessard M; Herry A; Berthou C; Léglise MC; Abgrall JF; Morice P; Flandrin G
    Leuk Res; 1998 Apr; 22(4):303-12. PubMed ID: 9669835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
    Lezon-Geyda K; Najfeld V; Johnson EM
    Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders.
    Neuman WL; Rubin CM; Rios RB; Larson RA; Le Beau MM; Rowley JD; Vardiman JW; Schwartz JL; Farber RA
    Blood; 1992 Mar; 79(6):1501-10. PubMed ID: 1347709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of the 5q- chromosome.
    Nagarajan L
    Leuk Lymphoma; 1995 May; 17(5-6):361-6. PubMed ID: 7549826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Submicroscopic deletions in 5q- associated malignancies.
    Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
    Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q.
    Gao Q; Horwitz M; Roulston D; Hagos F; Zhao N; Freireich EJ; Golomb HM; Olopade OI
    Genes Chromosomes Cancer; 2000 Jun; 28(2):164-72. PubMed ID: 10825001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome.
    de Souza Fernandez T; Menezes de Souza J; Macedo Silva ML; Tabak D; Abdelhay E
    Leuk Res; 1998 Feb; 22(2):125-34. PubMed ID: 9593469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.